Nihon Medi Physics Co.

Tokyo, Japan

Nihon Medi Physics Co.

Tokyo, Japan

Time filter

Source Type

There is provided a labeling precursor compound represented by the following general formula (2): wherein R_(1 )represents an alkynyl group, an alkynyloxy group, an azide group, an azidoalkyl group, an arylazide group, a monocyclic or condensed polycyclic aryl group or a nitrogen-containing heterocycle; R_(2 )and R_(3 )each independently represent an alkyl group or a hydroxyalkyl group which hydroxy group may be protected with a protecting group, and n is an integer of 1 or 2; R_(6 )represents an alkyl group or CONR_(11)R_(12 )wherein R_(11 )and R_(12 )each independently represent an alkyl group or a monocyclic or condensed polycyclic aryl group; and R_(4), R_(5), R_(7 )and R_(8 )each independently represent a hydrogen atom, an alkyl group or an alkoxy group.


There is provided a labeling precursor compound represented by the following general formula (2):_(1) represents an alkynyl group, an alkynyloxy group, an azide group, an azidoalkyl group, an arylazide group, a monocyclic or condensed polycyclic aryl group or a nitrogen-containing heterocycle; R_(2) and R_(3) each independently represent an alkyl group or a hydroxyalkyl group which hydroxy group may be protected with a protecting group, and n is an integer of 1 or 2; R_(6) represents an alkyl group or -CONR_(11)R_(12) wherein R_(11) and R_(12) each independently represent an alkyl group or a monocyclic or condensed polycyclic aryl group; and R_(4), R_(5), R_(7) and R_(8) each independently represent a hydrogen atom, an alkyl group or an alkoxy group.


Patent
Nihon Medi Physics Co., Kyoto University and National Hospital Organization | Date: 2017-05-03

Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. (In the formula, R_(1) represents a hydrogen atom or CO_(2)R_(a); R_(2) represents a hydrogen atom, a halogen atom, or CO_(2)R_(a); R_(3) represents a hydrogen atom or a C1-10 hydroxyalkyl group; R_(4) represents a hydrogen atom, a hydroxy group, or a C1-10 alkoxy group; R_(5) represents a C1-5 chain alkyl group in which the hydrogen atoms are optionally substituted with halogen atoms, a C3-5 cyclic alkyl group in which the hydrogen atoms are optionally substituted with halogen atoms, a C1-5 hydroxyalkyl group, or an o-, p-, or m-halobenzyl group; A represents CH or a nitrogen atom; X_(1) and X_(3) independently represent hydrogen atoms or halogen atoms; X_(2) represents a hydrogen atom, a halogen atom, or a nitrile group; at least one of X_(1), X_(2), and X_(3) represents a halogen atom; and R_(a) independently represents a C1-10 alkyl group.)


Patent
Yokohama City University and Nihon Medi Physics Co. | Date: 2017-05-17

A novel technique of quantifying nuclear medicine data is provided. The novel technique is characterized in that information acquired from nuclear medicine image data is normalized with bone mineral content (BMC) or bone mineral density (BMD). Some embodiments use, instead of the conventional SUV, the SUVbone that has been invented by the inventors of the present application such as the following: SUVbone = {Amount of attenuation-corrected radioactivity in region of interest (kBq) Volume of region of interest (ml)} / {Administered radioactivity dose (kBq) Bone mineral content (g)} or SUVbone = {Amount of attenuation-corrected radioactivity in region of interest (kBq) Volume of region of interest (ml)} / {Administered radioactivity dose (kBq) Bone mineral density (g/m^(2))}. BMC or BMD may be estimated from sex, age, height, or weight of a subject.


Patent
Nihon Medi Physics Co. | Date: 2017-05-17

To provide a technique for evaluating a nuclear medicine brain image, the technique being hardly affected by the difference in the setting of reference regions. An embodiment of the present invention generally includes: setting a reference region on a region corresponding to the scalp in the nuclear medicine brain image; calculating information on a pixel value in the set reference region; and normalizing, using the information, a pixel value of each pixel included in the nuclear medicine brain image or a value obtained from the pixel value, and outputting the normalized value.


Patent
Nihon Medi Physics Co. | Date: 2017-06-07

One embodiment of the present invention addresses the problem of reducing the influence of physiological accumulation in monitoring nuclear medical image data. To solve this problem, the embodiment comprises: extracting a bone area from CT image data having been positioned with nuclear medical image data; in the nuclear medical image data, displaying the data of an area overlapping the bone area extracted above; and, in the nuclear medical image data, not displaying the data of an area not overlapping the bone area extracted above.


Patent
Nihon Medi Physics Co., Kyoto University and National Hospital Organization | Date: 2015-06-25

Provided is a compound represented by general formula (1) or a salt thereof as well as a medicine containing the compound or the salt. In the formula, R_(1), R_(2), R_(3), R_(4), R_(5), X_(1), X_(2), and X_(3 )are defined.


Patent
Nihon Medi Physics Co. | Date: 2017-08-02

The present invention provides a renal imaging agent comprising a nitroimidazole-type compound or a salt thereof. The renal imaging agent according to the present invention can be used in positron emission tomography.


Patent
Nihon Medi Physics Co. | Date: 2015-10-01

It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [^(18)F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R^(1 )is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by OR^(2); R^(2 )is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R^(3 )is a protective group.


Patent
Nihon Medi Physics Co. | Date: 2015-03-04

One of the preferred embodiments includes: (a) creating a summed 3D nuclear medicine imaging data by summing a plurality of 3D nuclear medicine imaging data pixel by pixel, wherein each of the plurality of 3D nuclear medicine imaging data is associated with a different phase of a cardiac cycle; (b) determining pixels corresponding to myocardial regions in the summed 3D nuclear medicine imaging data; (c) defining a plurality of tracing directions based on the summed 3D nuclear medicine imaging data, and determining a reference myocardial center base point, a reference inner myocardial wall base point and a reference outer myocardial wall base point for each of the tracing directions; (d) determining a phase-specific myocardial center base point for each of the tracing directions for each of the phases based on the corresponding 3D nuclear medicine imaging data; and (e) seeking a difference between the reference myocardial center base point and the phase-specific myocardial center base point, and determining a phase-specific inner myocardial wall base point and a phase-specific outer myocardial wall base point by shifting the reference inner myocardial wall base point and the reference outer myocardial wall base point respectively based on the determined difference, for each of the tracing directions for each of the phases.

Loading Nihon Medi Physics Co. collaborators
Loading Nihon Medi Physics Co. collaborators